Novartis has high hopes for newly launched heart drug Leqvio and cancer therapy Pluvicto. To hear CEO Vas Narasimhan tell it, both products are off to a strong start in their multiyear journeys to ...
A Novartis sign hangs on the side of an office building in Cambridge, Massachusetts. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free ...
- Results highlight ATNM-400's potential as a transformative therapeutic option for prostate cancer patients with unmet clinical needs as expression of the target receptor for ATNM-400 persists ...
In the PSMAfore trial, Pluvicto reduced the risk of radiographic progression or death by 59%. The Food and Drug Administration (FDA) has expanded the approval of Pluvicto ® (lutetium Lu 177 vipivotide ...
Pluvicto, a drug used to treat advanced prostate cancer, is in short supply, the Food and Drug Administration reported last week. Novartis, the pharmaceutical company that manufactures Pluvicto, ...
COLUMBIA — Pluvicto, a radiopharmaceutical treatment for prostate cancer, will be available at Missouri Cancer Associates by the end of spring. The treatment is currently offered through a pilot ...
Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis, where Pluvicto (lutetium (177 Lu) vipivotide tetraxetan), plus standard of care (SoC), has ...
Novartis entered a new era after spinning off Sandoz earlier in October. As the pure-play innovative medicines company reports strong growth from the business it’s now built on, one product faces a ...
Pluvicto is a radioligand therapeutic agent containing the active moiety, lutetium-177, which binds to PSMA, a transmembrane protein that is expressed in prostate cancer. The Food and Drug ...
WEST LAFAYETTE, Ind. and NEW YORK -- Purdue Research Foundation, a private not-for-profit institute to advance the research of Purdue University, has received more than $100 million from Owl Rock, a ...
Doctors across the United States who treat people with advanced prostate cancer can’t find supplies of a medicine that may help them live longer. “We recognize that this situation is distressing for ...
The U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG’s (NYSE:NVS) Pluvicto for prostate cancer patients. The expanded indication, which approximately triples the number of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback